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Abstract  
 
Unfettered inflammation is thought to play critical role in the development of different 
clinical forms of tegumentary leishmaniasis. Eicosanoids are potent mediators of 
inflammation and tightly associated with modulation of immune responses. In this cross-
sectional exploratory study, we addressed whether targets from the eicosanoid 
biosynthetic pathway assessed through multiplexed expression assays in lesion biopsies 
as well as in plasma could highlight a distinct biosignature in patients with 
mucocutaneous leishmaniasis (MCL) or localized cutaneous leishmaniasis (LCL). 
Differences in immunopathogenesis between MCL from LCL may result from an 
imbalance between prostaglandins and leukotrienes, which may serve as targets for future 
host-directed therapies. 
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Background 
Tegumentary leishmaniasis is a vector-borne-disease caused by Leishmania 
parasites and exhibits a wide spectrum of clinical presentations. The most common 
clinical form of the disease caused by L. braziliensis parasites is the localized cutaneous 
leishmaniasis (LCL), characterized by ulcerated dermal lesions, which usually heal 
spontaneously [1]. A More severe form of this disease, mucocutaneous (MCL), is 
observed in 3% of individuals with LCL [2]. MCL patients usually present with severe 
and progressive destruction of nasopharyngeal and/or laryngeal structures [2]. MCL 
lesions exhibit an intense inflammation and tissue damage and paradoxically very few 
parasites. Necrosis of mucosal tissue is associated with a strong T-cell mediated response, 
reflected by an exacerbated delayed-type hypersensitivity (DTH) reaction to Leishmania 
antigens [3]. Possible mechanisms linked to increased disease severity in MCL are still 
unknown, but lack of immune modulation leading to uncontrolled inflammation seems to 
be critically involved [3].  
Eicosanoids have been described to regulate key aspects of the host immune 
responses during Leishmania infection [4]. Prostaglandin E2 (PGE2) has been shown to 
benefit parasite survival whereas increased Leukotriene B4 (LTB4) production leads to 
enhanced intracellular parasite killing by infected host cells [5, 6]. These findings suggest 
that the balance between prostanoids and leukotrienes may directly affect the capacity of 
the host to control Leishmania infection. However, whether this dichotomy in the 
expression of eicosanoids is relevant in the context of MCL remains unknown.  
Here, we perform a cross-sectional exploratory study in patients with MCL and 
LCL from an endemic area in Brazil assessing circulating levels as well as in situ RNA 
expression of mediators from the eicosanoid pathway. We identify a distinct biosignature 
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of MCL hallmarked by decreased expression of enzymes and receptors of prostaglandins 
and lipoxins compared with LCL. Moreover, plasma levels for PGE2 and LTB4 indicated 
that MCL patients are prone to skew the eicosanoid balance towards leukotrienes, 
whereas LCL individuals exhibit an enriched prostanoid signature. These distinct 
expression profiles have potential implications for the understanding of tegumentary 
leishmaniasis pathogenesis, which can lead to development of new host-directed 
therapies targeting the eicosanoid pathway. 
 
Patients and methods 
This study was approved by the institutional review board from Centro de 
Pesquisas Gonçalo Moniz, FIOCRUZ (number 136/2007). All clinical investigations 
were conducted according to the Declaration of Helsinki. Written informed consent was 
obtained from all participants or legal guardians and all data analyzed were anonymized.  
The present study assessed age and gender- matched MCL (n=13, 1.4 
male/female ratio, aged 59 ±17 years old) and LCL patients (n=29, 1.9 male/female ratio, 
aged 34 ±15 years old) (MCL vs. LCL age, P=0.894; gender distribution, P=0.921) 
recruited at our reference clinic in Jiquiriçá, Brazil. Individuals included in the present 
study were required to have no previous diagnosis of tegumentary leishmaniasis and to be 
treatment naïve. For plasma analyses, we included samples from 43 healthy endemic 
controls (age and gender matched with LCL and MCL) exhibiting negative DTH 
responses. LCL and MCL diagnosis was confirmed by the presence of ulcerated skin 
lesion or granulomatous mucosal lesion, respectively, in addition to at least one of the 
following positive tests: anti-Leishmania DTH, anti-Leishmania antibody titles or 
detection of Leishmania parasites in biopsy tissues by either immunohistochemistry or 
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qualitative polymerase chain reaction (PCR) assays. LCL patients exhibited a single or 
few ulcerated lesions for up to 2 months, while MCL patients had symptoms for a 
prolonged period (mean time of disease 10 ± 14 years) with mucosal lesions involving 
the nasal cavity (100%), pharynx (35%) and/or larynx (11%). Tissue samples from which 
we had high quality mRNA were obtained from a subset of 4 MCL and 7 LCL patients. 
These patients were similar to their respective groups with regard to age and gender (data 
not shown). Nasal mucosal samples were obtained from turbinoplasty nasal surgery and 
performed under local anesthesia. All tissue specimens were obtained before treatment.  
Total RNA was extracted from cryopreserved lesion biopsies using Trizol reagent 
(Invitrogen, Carlsbad, CA), with an additional purification step using RNeasy columns 
(Qiagen, Venlo, Netherlands) as previously described [7]. nCounter (NanoString 
Technologies, Seattle, WA) analysis was performed at the VIB MicroArray Facility 
(Leuven, Belgium) based on direct molecular bar coding of target RNA transcripts and 
digital detection [7]. The chosen targets were: PGES (PGE Synthase), PGDS (PGD 
Synthase), PGD2R (PGD 2 receptor), PTGFR (PGF receptor), PTGS1 (COX-1), PTGS2 
(COX-2), PLAS2G4A (Phospholipase S2G4A), PLA2G6 (Phospholipase 2G6), LXA4R 
(Lipoxin A4 receptor), PTGER1 (E-prostanoid receptor 1), PTGR2 (E-prostanoid 
receptor 2), PTGER3 (E-prostanoid receptor 3), PTGER4 (E-prostanoid receptor 4), 
ALOX15 (Arachidonate 15-lipoxygenase), ALOX12 Arachidonate 12-lipoxygenase, 
ALOX5 (Arachidonate 5-lipoxygenase). To account for differences in leukocyte 
infiltration between patient lesions, data were normalized for CD45, which encodes the 
pan-leukocyte marker CD45, detectable at the femtomolar range as previously reported 
[7].  
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Concentrations of PGE2, PGD2 and PGF2α, LTB4 and resolvin D1 (RvD1) were 
measured in cryopreserved EDTA-treated plasma samples from all patients using an 
enzyme-linked immunoassay (Cayman Chemical, Ann Harbor, MI).  
Median values with interquartile ranges (IQR) were used as measures of central 
tendency. For expression assays, Mann-Whitney test was used to compare the variables. 
Plasma values were compared using the Kruskal-Wallis test with Dunn’s multiple 
comparisons ad hoc test. Unsupervised two-way hierarchical cluster analyses (Ward’s 
method) with bootstrap were employed to test whether MCL and LCL patients can be 
grouped separately based of simultaneous assessment of plasma eicosanoids. Two models 
of Principal Component Analysis (PCA) were employed to test the contribution of PGE2 
levels to the power of the combined assessment of several eicosanoids to distinguish 
MCL from LCL cases. A P-value < 0.05 was considered statistically significant.  
 
Results and Discussion 
To characterize the eicosanoid signaling pathways expressed in situ during MCL and 
LCL, we performed a comprehensive analysis of targeted RNA transcripts isolated from 
mucosal vs. skin biopsies. The target transcripts were represented within the context of an 
eicosanoid signaling pathway using Ingenuity Pathway Analysis (Figure 1A). 
Remarkably, MCL patients exhibited a substantial down modulation in several genes 
from the prostaglandin pathway compared with those with LCL (Figure 1B). Among all 
the genes examined, we found that PGES, PTGER3, PGDS, PTGFR, PTGS1 and ALOX5 
expression were significantly lower whereas LXA4R expression was higher in MCL 
cases than in individuals with LCL (Figure 1C).  
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Interestingly, differences found in expression of constitutively expressed targets, 
such as PTGS1 gene/COX-1, and for the inducible isoforms, such as PTGS2 gene/COX-
2, indicate that LCL and MCL activate distinct prostaglandins synthase pathways. PGE2 
acts through four distinct G protein-coupled receptors, E-prostanoid (EP) 1, EP2, EP3 
and EP4 [8]. Once PGE2 binds to different receptors, it can activate different signaling 
pathways inducing multiple, and sometime paradoxical, effector functions. Notably, it 
has been reported that Leishmania major infection up-regulates EP1 and EP3 expression 
while down-regulating EP2 and EP4 in vitro [9]. Our analyses suggested that differential 
expression of EP3 might be an important parameter related to the pathogenesis of MCL 
and LCL. Our exploratory findings warrant the design of additional studies that assess the 
role of EP receptors signaling in leishmaniasis.  
We next tested whether the differences in gene expression observed in situ could 
be reflected in a distinct profile of plasma concentrations of in MCL and LCL patients. 
By quantifying plasma levels of PGE2, PGD2 and PGF2α, as well as LTB4 and RvD1, we 
found that LCL patients exhibited a distinct expression profile compared with MCL 
(Figure 2A). We observed that PGE2 levels were significantly higher in LCL cases 
compared with individuals with MCL (Figure 2B). Whether the augmented circulating 
levels of these prostanoids are directly related to the increased COX1/PTGS1 expression 
in skin lesions observed in LCL patients deserves future clarification. Importantly, 
compared with values detected in healthy endemic controls, PGD2, PGF2α, LTB4 and 
RvD1 were significantly lower in LCL patients (Figure 2B). Conversely, concentrations 
of all the eicosanoids, except for PGF2α, were undistinguishable between MCL and 
controls (Figure 2B). Noteworthy, levels of LTB4 were >1log higher in MCL patients 
than in LCL cases (Figure 2B). Leukotrienes are highly bioactive and minor differences 
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in plasma measurements could reflect major differences in inflammation, as observed in 
other disease models [10]. These results indicate that a down modulatory effect may be 
more relevant in LCL than in MCL compared to healthy donors. Thus, systemic 
mediators observed in LCL and MCL may be useful as biomarkers of active disease. 
Together, these observations led us to hypothesize that a balance in the circulating 
levels of lipid mediators is associated with differential inflammatory status observed in 
MCL or LCL. In this scenario, prostaglandins derived from cyclooxygenases would 
prevail over lipoxygenase-derived products in LCL patients compared with those with 
MCL. To test this hypothesis, we performed an unsupervised hierarchical cluster analysis 
in which plasma values of all the eicosanoids measures from MCL and LCL cases were 
inputted. We confirmed that simultaneous assessment of key prostaglandins, LTB4 and 
RvD1, could successfully segregate the different clinical groups evaluated (Figure 2C).  
RvD1, an important specialized pro-resolving mediator, is endogenously 
generated during the spontaneous resolution phase in many models of acute and chronic 
inflammation diseases [11]. Counterintuitively at a first glance, although our data reveals 
that there is no statistically significant difference for RvD1 plasma levels between LCL 
and MCL patients, we noticed a trend of RvD1 median levels to be approximately 1.2 log 
decreased in LCL compared with MCL (Figure 2B). Whether RvD1 participates in the 
control and resolution of inflammation or promotion of parasite survival in tegumentary 
leishmaniasis patients needs to be further investigated. 
Notably, to our knowledge, this is the first study to demonstrate increased levels 
of prostanoids in plasma of tegumentary leishmaniasis patients. Interestingly, we found 
that PGF2α was in general reduced in tegumentary leishmaniasis patients compared to 
controls (Figure 2B). Recent studies from our group reported that PGF2α is uniquely 
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involved in the cellular metabolism of Leishmania species and its immune evasion 
capacity in murine models [12, 13]. Modulation of the PGF2α production could be a 
potential mechanism by which the host restricts a key mediator for promotion of parasite 
growth. 
Strikingly, additional hierarchical clustering analyses confirmed that the groups of 
MCL and LCL patients could be better separated when data on only two eicosanoids, 
PGE2 and LTB4, were considered (Figure 2C). The balance between these eicosanoids 
has been described to determine clinical outcomes in other diseases [10]. Two models of 
PCA supported the idea that differential expression of PGE2 in plasma is probably the 
most important parameter leading to distinction between MCL and LCL patients (Figure 
2D). Importantly, values of PGE2/LTB4 ratio were >8-fold higher in LCL patients than in 
MCL cases (median and IQR: 5.3, 3.5-6.4 vs. 0.6, 0.1-0.8; P<0.0001). Thus, circulating 
levels of PGE2 and LTB4 could be tested as potential biomarkers of mucosal involvement 
in tegumentary leishmaniasis. Considering that MCL cases exhibit longer periods with 
disease prior to diagnosis and that this disease form may progress from localized lesions, 
it is possible that our results may be affected by illness duration. Prospective studies 
focused on early detection of MCL may help clarifying this issue. In addition, differences 
in the expression profile of these biomarkers may reflect distinctions in the infiltration of 
leukocytes in the lesions. Although MCL and LCL exhibit in general cellular infiltrates 
enriched for mononuclear cells, we have previously shown an important role for 
neutrophils contributing to inflammation in MCL [14]. Cellular analyses employing flow 
cytometry could be performed to extensively phenotype cellular subsets recruited to 
tegumentary lesions, thus elucidating associations between the leukocyte infiltrate and 
the differential eicosanoid expression described here. A limitation of the present study 
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was lack of assess to skin/mucosal biopsies from healthy endemic controls for 
comparison with those from leishmaniasis patients. In addition, we could not test 
correlations between eicosanoid expression and parasite burden in the lesions, because 
the parasite quantification was very low and the sensitivity of the histological technique 
was insufficient to provide reliable quantitative values in such small sample set of 
individuals from whom we had in situ data. Regardless, our data indicate that, 
eicosanoids pathways, and PGE2 in particular, may be explored as novel targets for 
therapeutic interventions of tegumentary leishmaniasis. 
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Figure legends 
 
Figure 1. Differential expression of selected genes of eicosanoid pathways in skin or 
mucosal lesions from patients with tegumentary leishmaniasis. Total RNA was 
extracted from lesion biopsy specimens for patients with LCL (n = 7) and those with 
MCL (n = 4). Indicated messenger RNA transcripts of host-specific cellular genes were 
quantified by nCounter (Nanostring), including the pan-leukocyte gene CD45, for 
normalization of immune infiltration into tissues. (A) The targeted genes were 
represented within the context of an eicosanoid signaling pathway using Ingenuity 
Pathway Analysis. Red and green colors infer higher or lower gene expression in MCL 
relative to LCL patients, respectively. (B) A representative profile of geometric mean 
values (log10-transformed) for indicated genes is displayed for each clinical group. (C) 
Scatter plots of gene expression relative to CD45 are shown. Lines represent median 
values and interquartile ranges. Data were compared using the Mann-Whitney test. 
*P<0.05 
 
 
Figure 2. Plasma concentrations of eicosanoids in patients with localized or mucosal 
cutaneous leishmaniasis. 
(A) Plasma levels of COX-2 derived prostanoids PGE2, PGD2 and PGF2α and well as 5-
LO derived lipid mediators LTB4 and RvD1 were compared between patients with 
localized (LCL; n=29) or mucosal (MCL; n=13) leishmaniasis as well as healthy endemic 
controls (EC; n=43). Data were compared using the Kruskal-Wallis test with Dunn’s 
multiple comparisons ad hoc test (*P<0.05, **P<0.01, ***P<0.001). Lines represent 
median values and interquartile ranges. (B) Univariate analyzes with scatter plots of the 
comparisons are shown. (C) A hierarchical clustering analysis (Ward’s method) was 
employed to test whether the overall expression profile of all the lipid mediators (upper 
panel) or just PGE2 and LTB4 (lower panel) in plasma could distinguish MCL from LCL 
cases. (D) Two principal component analysis (PCA) models were utilized to examine the 
contribution of PGE2 in explaining the differences observed between the LCL and MCL 
study groups. PC, principal component. 
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